The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
Tandem Meetings 2026 | The real-world outcomes of patients with functional high-risk myeloma receiving cilta-cel
In this video, Kenneth Lim, MBBS, Australian Centre for Blood Diseases, Monash University, Melbourne, Australia, briefly discusses the real-world outcomes of patients with functional high-risk multiple myeloma receiving ciltacabtagene autoleucel (cilta-cel), highlighting that functional high-risk status does not appear to be an independent poor prognostic factor. This interview took place virtually.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think there has been some clinical trial data as part of the CARTITUDE studies of patients with early relapse after frontline therapy, and it seems like the outcomes of CAR T-cell appear promising. However, you know, we didn’t have any real studies on functional high-risk. And there’s been a recent publication, a consensus statement by the EMN about the definitions of what constitutes functional high-risk...
I think there has been some clinical trial data as part of the CARTITUDE studies of patients with early relapse after frontline therapy, and it seems like the outcomes of CAR T-cell appear promising. However, you know, we didn’t have any real studies on functional high-risk. And there’s been a recent publication, a consensus statement by the EMN about the definitions of what constitutes functional high-risk. So, functional high risk in the absence of high-risk cytogenetics and a PFS of less than 18 months. So that’s the new definition. And so we basically wanted to see how these functional high-risk patients actually do with CAR-T therapy, in particular, cilta-cel. So, using a real-world data set done with the Mayo Clinic, we basically interrogated those risk factors. And what we found was that functional high-risk did not appear to be a significant poor prognostic factor in standard of care-treated cilta-cel patients, albeit retrospective, so I think this probably has to be investigated in larger real-world prospective studies.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
